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Abstract 
Background: Eradication of H. pylori is important goal in the management of 
uncomplicated peptic ulcer disease and other conditions associated with H.pylori. The 
survival capabilities of H. pylori in the stomach makes it difficult to eradicate and 
effective treatment requires multidrug regimens. 
Objectives: To study the efficacy of lansoprazole, Amoxicillin and metronidazole in the 
eradication of H. pylori.  
Methods: A total of 35 patients (22 males and 13 females) with gastro-duodenal inflammation and positive for H. 
pylori were studied. Gastro-duodenoscopy was repeated four weeks after completion of treatment to assess the healing 
of inflammation. Biopsies were taken from the stomach and tested for H. pylori before and after treatment. 
Results: Twenty eight patients (93%) reported improvement in symptoms. 
Eradication of H. pylori was confirmed with negative rapid urease test in 20(67%) patients. Complete healing of the 
gastro-duodenal inflammation was achieved in 22 patients (73%), partial healing in 6 patients, while only 2(7%) 
patients showed no healing. 
Conclusion: The reduced eradication rate of this drug combination in this study (67%) compared to a previous one 
(96%) could be explained partly by the development of antibiotic resistance (possibly to metronidazole) during the last 
few years.  
 




n developing countries, the prevalence of 
H. pylori may reach levels of 80 – 90% by 
20 years of age1. H. pylori are associated 
with the majority of duodenal and gastric 
ulcers2, 3. It has been classified by the WHO 
as type 1 carcinogen of the stomach since 
19944,5, 6. A significant proportion of patients 
do not respond to treatment. Antibiotic 
resistance is the major cause of treatment 
failure. Other causes of treatment failure are 
advanced age, smoking, high intra-gastric 
bacterial load before treatment, bacterial 
genotype and host genetic polymorphisms. 
Materials and methods: 
        This study was carried out in the period 
from April 2002 to October 2002. Thirty five 
patients with gastro-duodenal inflammation, 
and positive for H. pylori, were included in 
this study.   Gastric antral biopsies were taken 
and rapid urease test was used to test for the 
organism. 
 
Assistant Professor of Medicine, Department of 
Medicine The University of science and Technology. 
Omdurman - Sudan P.O. Box 722   Khartoum mobile 




All the patients were interviewed via a 
questionnaire. 
They were supplied with amoxicillin 1gm 
twice daily for one week, metronidazole 1gm 
twice daily for one week and lansoprazole 
30mg once daily for three weeks. The patients 
were followed up two weeks after 
commencement of treatment for improvement 
in symptoms, compliance and for reporting of 
side effects. 
Thirty patients came back for follow up. The 
patients were re-endoscoped four weeks after 
completion of treatment. Healing of gastro-
duodenal inflammation was assessed and two 
biopsies were taken, one from the antrum and 
the other from the body of the stomach. The 
biopsies were re-tested for H. pylori using 
rapid urease test.  
If both biopsies were negative, then treatment 
will be considered as successful. 
The data were entered into the computer and 
descriptive analysis was done by percentage. 
P values were calculated using the Chi-squire 
test. 
Results: 
      All 30 patients who continued their follow 
up received the full dose of triple therapy.  
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Twenty three (76.7%) patients, reported side 
effects to metronidazole (nausea and/or 
metallic taste). Two patients reported side 
effects to amoxicillin (diarrhoea). Only one 
patient suffered from headache attributed to 
lansoprazole. 
 
Table 1: Pattern of gastro-duodenal inflammation   
Type of gastroduodenal    
inflammation 
   No. of 
patients 
   % 
Gastritis 11 31 
Duodenitis 10 29 
Gastritis + Duodenitis 3 9 
Duodenal ulcer 11 31 
Total 35 35 
 
Twenty (57%) patients were of low 
socioeconomic status, 14(40%) patients were 
of moderate socioeconomic status and only 
one (3%) patient was of high socioeconomic 
status. Twenty eight (93%) patients reported 
improvement of symptoms within the first 
two weeks after commencement of treatment. 
Eight patients with duodenal ulcers showed 
complete ulcer healing. Rapid urease test was 
negative in 20(67%) patients and positive in 
10(33%) of patients. 
 
Table 2: The distribution of H. pylori in the stomach, in 
patients positive for H. pylori, 4 weeks after 
completion of treatment. 
 
The distribution of  H. 




Antrum only             5   50 
Body only             0 0 
Anrum + Body             5 50 
Total           10 100 
Discussion: 
          The infection was more prevalent among 
the groups of low socioeconomic status, 
which is consistent with other studies7. 
Comparison studies between developing and 
developed countries showed that the 
prevalence among middle aged adults is over 
80% in many developing countries as 
compared to 20 - 50% in developed 
countries8,9. 
A number of patients reported improvement 
in symptoms after completion of the therapy  
 
which is consistent with studies that showed 
significant symptomatic improvement to 
occur in patients who became H. Pylori 
negative in the absence of peptic ulceration10. 
The combination of amoxicillin, 
metronidazole and lansoprazole had achieved 
an eradication rate of 67% in our study. In 
many other studies, amoxicillin and 
metronidazole had achieved eradication rates 
of 78.9 - 82.8% according to intention-to-treat 
analysis11.  
A study was done in Sudan12 on the effect of 
triple therapy (amoxicillin, metronidazole and 
omeprazole) on the eradication of H. pylori 
infection in Sudanese patients had achieved 
an eradication rate of 96%. This discrepancy 
in the eradication rate of H. pylori may be 
explained partly by the development of 
resistance to metronidazole which is 
frequently used by the patients without 
prescriptions. However, a difference in 
efficacy in eradication of H. pylori between 
omeprazole and lansoprzole has to be 
considered among other factors.  
Metronidaole resistance ranges between 20% 
and 30% among both men and women in 
developing countries, because of its frequent 
use to treat other diseases13.  
 Most of the patients (77%) 
complained of nausea and/or metallic taste 
associated with metronidazole, 7% 
complained of diarrhoea due to amoxicillin 
and only 3% of patients complained of 
headache related to lansoprazole usage. These 
side effects are usually not severe and have 
not led to poor compliance in trials14,15. 
Local surveillance of antibiotic resistance to 
H. pylori is recommended to prevent primary 
failure of treatment. 
References:    
1. Suzanne M, David A P. Peptic ulcer disease and 
Helicobacter pylori. In: Peter R M, (Edi). GI/Liver 
Secrets. Philadelphia, United States: Hanely and 
Belfus, inc; 2001. P. 66-72. 
2. Feldman R A. Epidemiologic observations and open 
questions about disease and infection caused by 
Helicobacter pylori. In: Achrtman M, Suerbaum S (edi) 
Helicobacter pylori, Mollicular and cellular biology. 
Wymondham. United Kingdom: Horizon Scientific 
Press; 2001. p. 66-72. 
3. Schlemper R J, Van Der Werf S D, Biemond L, et al. 
Sero-epidemiology of gastritis in Japanese and Dutch 
male employees with and without ulcer disease. Eue 
Wadi AA & Fedail SS                                                                                                Lansoprazol as part of triple therapy 
 
© Sudan JMS Vol. 3, No. 1, Mar 2008                                         43 
 
 
Gastroenterol Hepatol 1996; 8: 33-39. 
4. Parsonnet J, Friedman G D, Vandersteen D P. 
Helicobacter pylori infection and the risk of gastric 
carcinoma. N Engl J Med 1991; 325: 1127-1131. 
5. Nomura A, Stemmermann G N, Chyou P-H Kato I, 
et al. Helicobacter pylori infection and gastric 
carcinoma among Japanese Americans in Hawaii. N 
Engl J Med 1991; 325: 1132-1136. 
6. Forman D, Newell D G, Fullerton F. Association 
between infection with Helicobacter pylori and risk of 
gastric cancer: Evidence from a prospective 
investigation. BMJ 1991; 325: 1132-1136. 
7. Malaty H M, Graham D Y. Importance of childhood 
socioeconomic status on the current prevalence of H. 
pylori infection. Gut 1994; 35: 742-45. 
8. Feldman R A. Epidemiologic observations and open 
questions about disease and infection caused by H. 
pylori. In: Achtman M, Suerbaum S (editors). H. pylori 
molecular and cellular biology. Wymondham, United 
Kingdom; Horizon Scientific Press. 2001; 29-51. 
9. Rowland M, Kumar D, Daly L. Low rates of H. 
pylori Re-infection in children. Gasroenterol 1999; 
117: 336-34. 
10. Laheij R J, Jansen J B, Van-de-Lisdonk EH. 
Symptom improvement through eradication of H. 
pylori in patients with non-ulcer dyspepsia. Aliment 
Pharmacol Ther 1996; 10(6): 843-850. 
11. Laheij R J, Rossum L G, Jansen J B, et al. 
Evaluation of treatment regimens to cure Helicobacter 
pylori infection - a meta-analysis. Aliment Pharmacol 
Ther 1999; 13:857-864. 
12- Personal contact 
13. Meyer J M, Silliman N P, Wang W. Risk factors 
for H pylori resistance in the United States: The 
surveillance of H pylori antimicrobial resistance 
partnership (SHARP) study, 1993-1999; Ann Intern 
Med 2002; 136: 13-24. 
14. Chiba N, Hunt R H. Bismuth, metronidazole and 
tetracycline and acid suppression in H pylori 
eradication: a meta-analysis. Gut 1996; 39: 36-37. 18. 
15. Lerang F, Moum B, Ragnhildsveit E, et al.  A 
comparison between omeprazole-based triple therapy 
and bismuth-based triple therapy for the treatment of 
Helicobacter pylori infection: a prospective 
randomized 1-year follow-up study. Am J 
Gastroenterol 1997; 92: 653-658. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
